Children’s Medical Center has patented a method for enhancing immune responses in dendritic cells using 1-palmitoyl-2-arachidonyl-sn-glycero phosphorylcholine (PAPC) and its oxidized form (oxPAPC) as adjuvants in vaccines, alongside specific TLR agonists and immunogens from infectious agents. GlobalData’s report on Children’s Medical Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Children's Medical Center, was a key innovation area identified from patents. Children's Medical Center's grant share as of July 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Immunostimulatory compositions for activating dendritic cell responses
The patent US12070499B2 describes a pharmaceutical composition designed to enhance immune responses through the inclusion of specific immune system modulators. The composition comprises a combination of a TLR (Toll-like receptor) agonist—specifically TLR4, TLR2, and/or TLR9 agonists—an oxidated form of 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (oxPAPC), and an immunogen derived from an infectious agent. Notable examples of TLR agonists mentioned include lipopolysaccharide (LPS) and monophosphoryl lipid A (MPLA) for TLR4, Pam3CSK and Pam2CSK for TLR2, and CpG for TLR9. The oxPAPC species can include various chemical structures, such as HOdiA-PC, KOdiA-PC, HOOA-PC, KOOA-PC, and PEIPC.
The immunogen component of the composition is versatile, encompassing antigens from viruses, bacteria, amoebas, and protozoa. Specific examples of viral antigens include those from human papilloma virus, herpes viruses, retroviruses, hepatitis viruses, and various respiratory viruses. Bacterial antigens are also detailed, with examples including those from Mycoplasma pneumoniae, Salmonella, Staphylococcus, and Mycobacterium. Additionally, the composition can target protozoan antigens, such as those from malaria and Trypanosoma cruzi. This patent outlines a comprehensive approach to developing a pharmaceutical composition that aims to stimulate the immune system against a wide range of infectious agents.
To know more about GlobalData’s detailed insights on Children's Medical Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
